Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression
Xiao-Mei Peng, Xin-Peng Shi, Han Chen, Lu-Yang Cao, Hao-Jian Zuo, Jie-Qiong Guo, Nan Jiang, Xiao-Yong Luo · 2025
Read Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression by Xiao-Mei Peng, Xin-Peng Shi, Han Chen, Lu-Yang Cao, Hao-Jian Zuo, Jie-Qiong Guo, Nan Jiang, Xiao-Yong Luo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12748097.txt.
Description
A gene-silencing enzyme, DNMT1, runs high in colorectal cancer and helps it grow and spread. Xiao-Mei Peng and co-authors map a feedback loop around it. The enzyme silences a second gene, TRAF6, by methylating its promoter. That second gene's protein normally tags DNMT1 for destruction, so silencing it lets DNMT1 pile up.
The drug decitabine breaks the loop, sending DNMT1 to the disposal pathway and freeing TRAF6. DNMT1 also shields a cancer-promoting partner, EZH2, from the same disposal route. Patient tissue checks confirmed the inverse pattern. The 2025 study reveals a self-reinforcing circuit and a drug that cuts it at two points.
Catalog record
| CREATOR | Xiao-Mei Peng, Xin-Peng Shi, Han Chen, Lu-Yang Cao, Hao-Jian Zuo, Jie-Qiong Guo, Nan Jiang, Xiao-Yong Luo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |